Skip to content
Screener

Harrow HROW Deferred Revenue

Deferred Revenue at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$684.8M+42.1%
PTH
Pelthos TherapeuticsPTHS
$978K

Other financials

Income statement

See full
Revenue$70.7M+10.9%
Gross profit$50.4M+6.0%
Operating income-$11.0M-196%
Net income-$17.3M-446%
EPS (diluted)-$0.46-454%

Balance sheet

See full
Cash & equivalents$83.9M+58.4%
Total debt$308.4M-32.0%
Total equity$15.2M-69.4%
Total assets$416.8M+20.8%

Cash flow

See full
Operating cash flow-$9.8M
CapEx$491.0K+196%
Free cash flow-$10.2M

Valuation

See full
Market cap$1.51B+22.5%
Enterprise value$1.73B+6.3%
P/S5.5×+0.1×

Profitability

See full
Gross margin73.3%-1.3pp
Operating margin-1%-7.3pp
Net margin-19.8%+18.0pp
FCF margin1.8%+1.3pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity20.3×+11.2×
Current ratio2.2×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The source filing: Harrow’s 10-Q, filed August 10, 2026. Open the filing →

Filed
Aug 10, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055271

FAQ

What is Harrow's deferred revenue?
Harrow (HROW) reported deferred revenue of $106K in Q2 2026.
How has Harrow's deferred revenue changed year-over-year?
Harrow's deferred revenue increased by 16.5% year-over-year, from $91K to $106K.
What is the long-term trend for Harrow's deferred revenue?
Over 5 years (2020 to 2025), Harrow's deferred revenue has grown at a 64.2% compound annual growth rate (CAGR), from $66K to $788K.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.

Ask your AI about Harrow's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude